Clean Science and Technology reported a 22% year-on-year revenue increase to Rs 299 crore for the second quarter of fiscal 2027. Despite this volume-led growth, the company faced margin compression due to elevated raw material costs and intense competition. Investors are now tracking the performance of the HALS segment and the execution of new capacity expansion plans.
Clean Science and Technology’s financial performance for the second quarter of fiscal year 2027 highlights a period of volume-led growth balanced against ongoing profitability challenges. The company reported consolidated revenue of Rs 299 crore, marking a 22% increase compared to the same period in the previous year. This growth was largely driven by demand in the HALS (Hindered Amine Light Stabilizers) segment, which has become a key contributor to the company’s sales mix.
While the top line expanded, the company’s bottom line growth remained muted. Consolidated profit after tax (PAT) stood at Rs 56 crore, showing marginal growth year-on-year. The EBITDA margin declined to 31.2%, down from 36.4% in the same quarter last year. This contraction is primarily due to higher raw material costs—specifically for phenol and acetone—which accounted for a significant portion of revenue. Additionally, the company faces pricing pressure in its segment, driven by aggressive competition from international players, particularly from China, which has limited the firm's ability to pass on cost increases to customers.
The HALS business is a central focus for the company’s growth strategy. Currently, capacity utilization in this segment stands at approximately 40%, with management targeting a ramp-up to 55% to 60% in the coming quarters. Clean Fino Chem, a subsidiary, has also completed trials for advanced HALS grades in collaboration with Geneus Chem AG, with commercial shipments expected to begin in the second half of the current fiscal year. This project represents a shift toward higher-grade products, which the company hopes will support long-term margin recovery.
The company is currently in a transition phase, moving from a period of heavy investment to asset monetization. Beyond the HALS segment, the firm expects its Performance Chemicals II facility to commence commercial production in the fourth quarter of fiscal 2027. The successful ramp-up of these facilities will be important to monitor, as they are intended to support future growth and reduce reliance on older product lines.
For investors, the key monitorable remains the balance between growth and profitability. While the expansion into new capacities and advanced chemical grades offers a path for long-term growth, execution risk is a reality. The ability of the company to improve capacity utilization, manage input costs, and navigate a competitive global pricing environment will determine its future margin trend. Investors will likely look for updates on these factors in the coming quarterly results.